CA2895574C - Utilisation du 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'atherosclerose - Google Patents

Utilisation du 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'atherosclerose Download PDF

Info

Publication number
CA2895574C
CA2895574C CA2895574A CA2895574A CA2895574C CA 2895574 C CA2895574 C CA 2895574C CA 2895574 A CA2895574 A CA 2895574A CA 2895574 A CA2895574 A CA 2895574A CA 2895574 C CA2895574 C CA 2895574C
Authority
CA
Canada
Prior art keywords
carboxy
aminium
dimethylpropan
ethyl
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2895574A
Other languages
English (en)
Other versions
CA2895574A1 (fr
Inventor
Ivars Kalvins
Reinis Vilskersts
Osvalds Pugovics
Maija Dambrova
Ilmars Stonans
Janis Kuka
Edgars Liepins
Einars Loza
Viktors ANDRIANOVS
Solveiga Grinberga
Daina Gustina
Daina LOLA
Marina Makrecka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grindeks JSC
Original Assignee
Grindeks JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks JSC filed Critical Grindeks JSC
Publication of CA2895574A1 publication Critical patent/CA2895574A1/fr
Application granted granted Critical
Publication of CA2895574C publication Critical patent/CA2895574C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne l'utilisation du 3-carboxy-N-éthyl-N,N-diméthylpropan-1-aminium et de ses sels pharmaceutiquement acceptables : le fumarate hydrogéné du 3-carboxy-N-éthyl-N,N-diméthylpropan-1-aminium et le phosphate hydrogéné du 3-carboxy-N-éthyl-N,N-diméthylpropan-1-aminium, pour la prévention et le traitement de l'athérosclérose.
CA2895574A 2012-12-20 2013-12-19 Utilisation du 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'atherosclerose Active CA2895574C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12198627.7 2012-12-20
EP12198627 2012-12-20
PCT/EP2013/077291 WO2014096133A1 (fr) 2012-12-20 2013-12-19 Utilisation du 3-carboxy-n-éthyl-n,n-diméthylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'athérosclérose

Publications (2)

Publication Number Publication Date
CA2895574A1 CA2895574A1 (fr) 2014-06-26
CA2895574C true CA2895574C (fr) 2019-11-26

Family

ID=47458734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895574A Active CA2895574C (fr) 2012-12-20 2013-12-19 Utilisation du 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'atherosclerose

Country Status (11)

Country Link
CN (1) CN104869988B (fr)
AR (1) AR094084A1 (fr)
BR (1) BR112015014161B1 (fr)
CA (1) CA2895574C (fr)
CU (1) CU20150067A7 (fr)
JO (1) JO3117B1 (fr)
MX (1) MX362762B (fr)
PE (1) PE20151587A1 (fr)
TN (1) TN2015000236A1 (fr)
WO (1) WO2014096133A1 (fr)
ZA (1) ZA201505093B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149654A1 (fr) * 2009-06-25 2010-12-29 Grindeks, A Joint Stock Company Composition pharmaceutique de gamma-butyrobétaïne ou sel pharmaceutiquement acceptable et de meldonium ou sel pharmaceutiquement acceptable
EA021588B1 (ru) * 2009-06-25 2015-07-30 Тетра Сиа Бетаиновые соли ацетилсалициловой кислоты
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
CA2832693C (fr) * 2011-04-27 2018-10-02 Grindeks, A Joint Stock Company Utilisation de sels de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium pour traiter une maladie cardiovasculaire

Also Published As

Publication number Publication date
BR112015014161B1 (pt) 2021-02-17
CA2895574A1 (fr) 2014-06-26
CN104869988A (zh) 2015-08-26
WO2014096133A1 (fr) 2014-06-26
TN2015000236A1 (en) 2016-10-03
PE20151587A1 (es) 2015-12-05
JO3117B1 (ar) 2017-09-20
MX362762B (es) 2019-02-06
ZA201505093B (en) 2016-04-28
AR094084A1 (es) 2015-07-08
CN104869988B (zh) 2017-07-28
MX2015008138A (es) 2016-04-25
CU20150067A7 (es) 2016-01-29
BR112015014161A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
JP7285903B2 (ja) ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法
US9308189B2 (en) Nitro fatty acids—neuroprotection and/or inhibition of cognitive decline
JP5575655B2 (ja) 腎保護剤としての中鎖長脂肪酸およびグリセリド
JP2011502997A5 (fr)
JP2004525080A (ja) 血漿リポタンパク質及び心臓血管疾患の危険因子を減ずるための組成物及び方法
JP2016506391A5 (fr)
US8765776B2 (en) Antihypertensive pharmaceutical composition
JP2009513713A5 (fr)
US9364490B2 (en) Use of derivatives containing C—O—P bonds in patients with kidney failure
JP2017536380A (ja) １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
HU227042B1 (en) Compostion for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
JP2008535907A5 (fr)
CA2895574C (fr) Utilisation du 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'atherosclerose
RU2015126505A (ru) Применение и способы лечения заболеваний и патологических состояний печени
MX2012000303A (es) Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
JP2016503035A5 (fr)
US20110117070A1 (en) Compositions and methods for treating headache
JP2011509257A5 (fr)
CN110913860A (zh) 调释烟酰胺
US20220000889A1 (en) Inositol phosphate compounds for use in increasing tissular perfusion
ITRM990483A1 (it) Composizione per la prevenzione e cura delle disfunzioni e patologie renali di tipo tossico e funzionale.
US20100234459A1 (en) Medicall use of 3-(2,2,2,-trimethylyhdrazinium) propionate hdrogen fumarate and dihydrogen phosephate
US20030040507A1 (en) Pharmaceutical composition comprising ifosfamide and carnitine
ITRM990436A1 (it) Composizione ad azione cardioattiva comprendente l-carnitina e suoi derivati ed estratti di crataegus.
JP2010508253A5 (fr)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180824